CurrentOscar HealthPolicy N/A

Biomarkers for Myocardial Infarction and Chronic Heart Failure

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage and medical-necessity criteria for cardiac biomarker testing used to evaluate acute coronary syndrome, myocardial infarction, dyspnea, and chronic heart failure. It applies to providers submitting claims for covered members, subject to the member’s benefit coverage, state of residence, contracts, and applicable policies.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentOscar HealthPolicy N/A

Biomarkers for Myocardial Infarction and Chronic Heart Failure

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerOscar Health

PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure

Policy CodePolicy N/A

Change TypeNon-material update

Effective DateJan 1, 202757d

Last ReviewSep 28, 2026

Next Review DateN/A

Key ActionFor acute coronary syndrome evaluation, perform testing at an outpatient facility capable of an adequate clinical myocardial infarction evaluation.

SourceLink

POLICY UPDATE CHANGES

The policy was updated on September 28, 2026, including policy background, guidelines and recommendations, and evidence-based scientific references.

4Maximum quantitative troponin measurements within the first 72 hours

4/yearMaximum BNP or NT-proBNP measurements for outpatient heart failure severity

2Covered heart failure biomarker categories

10+Cardiac biomarkers or testing approaches not meeting criteria

15CPT/HCPCS procedure codes listed

Coverage Criteria

Acute myocardial infarction evaluation

Covered when all of the following are met:

Quantitative troponin criteria

Acute coronary syndrome presentation: The individual presents with signs and symptoms of acute coronary syndrome.
See Note 1 in the policy.
Appropriate evaluation setting: Testing is performed at an outpatient facility capable of performing an adequate clinical myocardial infarction evaluation.
Quantitative testing and frequency: Quantitative cardiac troponin T or I is used for diagnosis of myocardial infarction.Up to 4 measurements within the first 72 hours following initial presentation

Heart failure evaluation and severity assessment

BNP or NT-proBNP measurement meets criteria when any of the following indications applies:

Covered indications

Heart failure diagnosis: The individual presents with dyspnea and testing is used to diagnose heart failure.
Chronic heart failure severity: Testing is used to establish disease severity in an individual with chronic heart failure in the outpatient setting.Up to 4 times per year

Biomarkers not meeting criteria for MI diagnosis or prognosis

The following testing does not meet criteria when performed for diagnosis or prognosis of myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome:

Excluded biomarker testing

Excluded biomarker: C-reactive protein is requested for diagnosis or prognosis of myocardial infarction.
Excluded biomarker: Heart-type fatty acid binding protein (H-FABP) is requested for diagnosis or prognosis of myocardial infarction.
Excluded biomarker: Any other cardiac biomarker not listed in the policy is requested for diagnosis or prognosis of myocardial infarction.

Guideline recommendations for cardiac biomarker use

The following clinical guideline recommendations are informational and are not explicit payer coverage criteria:

Guideline-supported biomarker uses

Suspected acute coronary syndrome: Measure cardiac troponin as soon as possible, preferably using a high-sensitivity assay.
If the initial result is nondiagnostic, perform serial measurement.
Suspected acute myocardial infarction: Interpret a rising and/or falling cardiac troponin pattern with at least one value above the 99th-percentile upper reference limit in the setting of clinical evidence of ischemia.At least one value above the 99th-percentile upper reference limit
Dyspnea with suspected heart failure: Measure BNP or NT-proBNP to support diagnosis or exclusion of heart failure when the cause of dyspnea is unclear and physical examination is equivocal.

Myocardial infarction diagnostic criteria

MI diagnosis requires both the biomarker criterion and at least one additional clinical, ECG, imaging, or angiographic criterion:

MI diagnostic requirements

Biomarker criterion: Detect a rise and/or fall of cardiac biomarker values, preferably cardiac troponin, with at least one value above the 99th percentile of the upper reference limit.At least one value above the 99th percentile of the upper reference limit
At least 1 additional criterion
- Symptoms of ischemia.
- New or presumed new significant ST-T changes or new left bundle branch block.
- Development of pathological Q waves on ECG.

Suspected acute coronary syndrome criteria

For suspected ACS, cardiac troponin is the preferred biomarker:

Suspected ACS biomarker assessment: Measure a biomarker of cardiomyocyte injury, preferably high-sensitivity cardiac troponin, in patients with suspected acute coronary syndrome.

Biomarkers other than cardiac troponin are not recommended for ACS diagnosis unless cardiac troponin is unavailable; CK-MB, myosin-binding protein C, or copeptin may have limited relevance in combination with standard cardiac troponin.

Suspected heart failure criteria

BNP or NT-proBNP is recommended for assessment of suspected heart failure:

Suspected heart failure assessment: Measure BNP or NT-proBNP in patients with suspected signs and symptoms of heart failure.

Population-level screening for heart failure is not supported by current ESC guideline recommendations; targeted screening is described for selected high-risk populations.

AST/SGOT measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

CKMB measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Creatine kinase (CK) measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Creatine kinase isoenzyme measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Lactate dehydrogenase (LD/LDH) measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Myoglobin measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Cardiac biomarker testing for acute coronary syndrome does not meet criteria when performed in an outpatient setting that cannot perform an adequate clinical myocardial infarction evaluation, including an independent laboratory or physician’s office.

In the outpatient setting, qualitative cardiac troponin T or I measurement does not meet criteria.

Copeptin measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Troponin C measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

C-reactive protein measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Heart-type fatty acid binding protein (H-FABP) measurement does not meet criteria when used to diagnose or provide prognosis for myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

C-reactive protein measurement does not meet criteria for diagnosis or prognosis of myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

H-FABP measurement does not meet criteria for diagnosis or prognosis of myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Measurement of any other cardiac biomarker not listed in the policy does not meet criteria for diagnosis or prognosis of myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome.

Serial BNP or NT-proBNP measurements should not be treated as established guidance for heart failure treatment because evidence remains insufficient to support treatment guidance based on serial values.

Newer biomarkers may provide prognostic information beyond natriuretic peptides, but they do not have established evidence of an incremental management benefit.

Copeptin is not encouraged for myocardial infarction assessment because troponins are generally superior.

For acute coronary syndrome diagnosis, biomarkers other than cardiac troponin are not recommended unless cardiac troponin is unavailable. CKMB, myosin-binding protein C, or copeptin may have limited relevance in combination with standard troponin in specific circumstances.

Current ESC guidance does not support population-level screening for heart failure. Targeted screening may be considered for selected high-risk populations.

The listed testing approaches and biomarkers do not meet criteria because published scientific literature is lacking to confirm that they are required and beneficial for diagnosis and treatment of the individual’s illness.

Covered Clinical Indications

Quantitative troponin T or I for MI evaluation in symptomatic ACS patients

Covered when all of the following are met:

Quantitative troponin T or I for MI evaluation

The patient presents with signs and symptoms of acute coronary syndrome.
Quantitative cardiac troponin T or I is ordered for diagnosis of myocardial infarction.
Testing is performed at an outpatient facility capable of performing an adequate clinical myocardial infarction evaluation.
Testing does not exceed four measurements within the first 72 hours following initial presentation.Up to 4 measurements within 72 hours

Coding and Clinical Thresholds

Applicable CPT/HCPCS Procedure CodesCPT

82550	Creatine kinase (CK), (CPK); total
82552	Creatine kinase (CK), (CPK); isoenzymes
82553	Creatine kinase (CK), (CPK); MB fraction only
82554	Creatine kinase (CK), (CPK); isoforms
82725	Fatty acids, nonesterified
83615	Lactate dehydrogenase (LD), (LDH);
83625	Lactate dehydrogenase (LD), (LDH); isoenzymes, separation and quantitation
83874	Myoglobin
83880	Natriuretic peptide
84450	Transferase; aspartate amino (AST) (SGOT)

1–10 of 15

1/2

Cardiac troponin myocardial injury threshold

ThresholdAbove the assay-specific 99th percentile upper reference limit

AnalyteCardiac troponin concentration

IndicationIndicative of myocardial injury

Repeat high-sensitivity cardiac troponin interval

Repeat interval1 to 2 hours

TestHigh-sensitivity cardiac troponin

When usedWhen the initial value is nondiagnostic

Provider Actions and Denial Risks

Documentation Required

Accurate Documentation, Coding, and Billing Required

Providers are responsible for submitting accurate documentation of services performed and coding claims according to applicable industry-standard coding and billing guidelines. Failure to follow appropriate coding, billing, or reimbursement policies may result in claim denial and/or recoupment of payment.

Use applicable Uniform Billing Editor, AMA/CPT, CPT Assistant, HCPCS, ICD-10-CM/PCS, NDC, DRG, CMS National Correct Coding Initiative, CCI edits, and other CMS guidelines as appropriate.
Coverage does not guarantee reimbursement; services must also meet authorization, medical-necessity, benefit, and applicable state requirements.

Denial Risk

Outpatient Evaluation Capability Required

For individuals presenting with signs and symptoms of acute coronary syndrome, cardiac biomarker measurement in an outpatient setting that cannot perform an adequate clinical myocardial infarction evaluation does not meet criteria and is subject to denial.

Background

Cardiac biomarkers are biochemical markers released into the blood from injured myocardial tissue in acute and chronic conditions, including myocardial infarction and heart failure. Troponin and CK-MB are used in acute clinical settings, while natriuretic peptides support heart failure evaluation and prognosis. This policy identifies covered uses of quantitative troponin, BNP, and NT-proBNP and excludes specified biomarkers and testing approaches for the indications described.

Definitions and Abbreviations

Quantitative cardiac biomarker measurement

Test typeBlood test

Myocardial infarction useQuantitative measurement of troponin T or troponin I for myocardial infarction diagnosis

Heart failure useBNP or NT-proBNP measurement for heart failure evaluation

Acute coronary syndrome definition

Clinical presentationSigns and symptoms for which myocardial infarction evaluation may be required

EvaluationMay require myocardial infarction evaluation

Policy reference

Frequency and Repeat Testing Limits

Quantitative cardiac troponin T or I frequency limit

TestQuantitative cardiac troponin T or I

LimitUp to 4 measurements

PeriodFirst 72 hours following initial presentation

BNP or NT-proBNP chronic heart failure severity frequency limit

TestBNP or NT-proBNP

LimitUp to 4 measurements

PeriodPer year in the outpatient setting

Ordering Requirements

Documentation Required

Verify facility capability before ordering ACS biomarkers

For acute coronary syndrome evaluation, perform cardiac biomarker testing at an outpatient facility capable of performing an adequate clinical myocardial infarction evaluation. Independent laboratories and physician’s offices are examples of settings that do not meet criteria.

Not Covered Services

The following do not meet criteria for the specified acute coronary syndrome or myocardial infarction indications: AST/SGOT, CKMB, CK, creatine kinase isoenzymes, LD/LDH, myoglobin, copeptin, troponin C, C-reactive protein, H-FABP, and any other cardiac biomarker not listed in the policy. Testing also does not meet criteria when performed in an outpatient setting unable to complete an adequate clinical myocardial infarction evaluation or when cardiac troponin is measured qualitatively.

Policy Summary

PayerOscar Health

PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure

Policy CodePolicy N/A

Change TypeNon-material update

Effective DateJan 1, 202757d

Last ReviewSep 28, 2026

Next Review DateN/A

Key ActionFor acute coronary syndrome evaluation, perform testing at an outpatient facility capable of an adequate clinical myocardial infarction evaluation.

SourceLink

On This Page

Class 1, Level A recommendation.

Chronic heart failure: Measure BNP or NT-proBNP for risk stratification.

Class 1, Level A recommendation.

Hospitalized heart failure: Measure BNP or NT-proBNP at admission to establish prognosis and consider a predischarge level to inform trajectory and postdischarge prognosis.

Patients at risk of developing heart failure: Consider BNP- or NT-proBNP-based screening followed by team-based care including a cardiovascular specialist.

Class 2a, Level B-R recommendation.

Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

Identification of an intracoronary thrombus by angiography.

BNP or NT-proBNP for heart failure diagnosis in patients with dyspnea

Covered for the following indication:

Heart failure diagnosis: The patient presents with dyspnea and BNP or NT-proBNP is measured to diagnose heart failure.

BNP or NT-proBNP for chronic heart failure severity assessment

Covered when all of the following are met:

Chronic heart failure severity assessment

The patient has chronic heart failure.
BNP or NT-proBNP is measured to establish disease severity.
Testing is performed in the outpatient setting.
Testing does not exceed four measurements per year.Up to 4 measurements per year

Cardiac troponin evaluation of suspected ACS, myocardial injury, or AMI

Covered for evaluation of suspected ACS, myocardial injury, or acute myocardial infarction:

Cardiac troponin evaluation

Measure cardiac troponin, preferably high-sensitivity cardiac troponin, when ACS, myocardial injury, or acute myocardial infarction is suspected.
When the initial result is nondiagnostic, perform serial testing.
Repeat testing is recommended at 1 to 2 hours for high-sensitivity assays and 3 to 6 hours for conventional assays.
Interpret results using clinical evidence of ischemia and the assay-specific 99th-percentile upper reference limit.

BNP or NT-proBNP for heart failure diagnosis or exclusion in dyspnea

Covered when BNP or NT-proBNP provides diagnostic support in a patient with dyspnea:

Heart failure diagnosis or exclusion

The patient presents with dyspnea.
The cause of dyspnea is unclear or the physical examination is equivocal.
BNP or NT-proBNP is measured to support diagnosis or exclusion of heart failure.

BNP or NT-proBNP for chronic heart failure risk stratification and prognosis

Covered for chronic heart failure risk stratification and prognosis:

Covered chronic heart failure uses

The patient has chronic heart failure and BNP or NT-proBNP is measured for risk stratification.
The patient is hospitalized for heart failure and BNP or NT-proBNP is measured at admission to establish prognosis.
The patient is hospitalized for heart failure and a predischarge BNP or NT-proBNP level is measured to inform trajectory and establish postdischarge prognosis.

Natriuretic peptide screening in selected patients at risk for heart failure

Covered for selected patients at risk of developing heart failure:

Targeted heart failure risk screening

The patient is selected because of increased risk of developing heart failure.
BNP- or NT-proBNP-based screening is performed.
Screening is followed by team-based care including a cardiovascular specialist.
Population-level screening is not supported; targeted screening is described for selected high-risk populations.

High-sensitivity cardiac troponin for suspected ACS or MI

Covered for suspected ACS or myocardial infarction:

High-sensitivity cardiac troponin assessment

The patient has suspected acute coronary syndrome or myocardial infarction.
High-sensitivity cardiac troponin is used as the preferred biomarker of cardiomyocyte injury.
Serial testing may be performed when needed for early rule-out or when the initial result is nondiagnostic.

BNP or NT-proBNP for suspected heart failure

Covered for patients with suspected heart failure:

Suspected heart failure biomarker assessment

The patient has suspected signs or symptoms of heart failure.
BNP or NT-proBNP is measured to support assessment and help confirm or exclude suspected heart failure.

Heart failure risk assessment or early detection in adults with diabetes

Guideline-supported use in adults with diabetes includes the following:

Heart failure risk assessment or early detection

The patient is an adult with diabetes.
Biomarker option
- Measure a natriuretic peptide, BNP or NT-proBNP.
- Measure high-sensitivity cardiac troponin.
Testing is performed at least yearly to identify early heart failure stages and support preventive strategies.At least yearly

Predischarge BNP or NT-proBNP for hospitalized heart failure

Covered for hospitalized patients with heart failure:

Predischarge heart failure assessment

The patient is hospitalized for heart failure.
A predischarge BNP or NT-proBNP level is measured.
The result is used to assess the patient's trajectory and establish postdischarge prognosis.

Repeat conventional cardiac troponin interval

Repeat interval3 to 6 hours

TestConventional cardiac troponin

When usedWhen the initial value is nondiagnostic

Single-value high-sensitivity troponin clinical decision pathway

TimingObtain troponin at least 3 hours after symptom onset

AssaySingle-value high-sensitivity cardiac troponin

PathwayClinical decision pathway incorporating a single hs-cTn value

H-FABP diagnostic cutoff

Cutoff5.7 ng/mL

TestHeart-type fatty acid binding protein (H-FABP)

Study contextEarly diagnosis of acute myocardial infarction

Approximate NT-proBNP to BNP equivalence

NT-proBNPGreater than 900 pg/mL

Approximate equivalent BNPGreater than 100 pg/mL

RelationshipNT-proBNP greater than 900 pg/mL is roughly equivalent to BNP greater than 100 pg/mL

Cardiac troponin criterion for MI diagnosis

Biomarker patternRise and/or fall of cardiac biomarker values

ThresholdAt least one value above the 99th percentile of the upper reference limit

Additional requirementAt least one clinical, electrocardiographic, imaging, or angiographic criterion

High-sensitivity troponin rule-out testing threshold

Rule-out thresholdAt or near the assay limit of detection, or the assay-specific 99th percentile threshold

TestHigh-sensitivity troponin

UseHelp rule out NSTEMI in patients with chest pain and suspected acute coronary syndrome

Post-PCI CK-MB threshold with normal baseline

Primary threshold>10x local laboratory ULN within 48 hours

Alternative threshold>5x ULN with new pathologic Q-waves in more than 2 contiguous leads or new persistent LBBB

BaselineNormal CK-MB baseline

Post-PCI cardiac troponin threshold with normal baseline

Primary threshold>70x local laboratory ULN within 48 hours

Alternative threshold>35x ULN with new pathologic Q-waves in more than 2 contiguous leads or new persistent LBBB

BaselineNormal baseline cardiac troponin

Serial high-sensitivity troponin sampling interval

Second sample30 minutes to 3 hours after the initial assessment sample

TestHigh-sensitivity cardiac troponin

Sampling planInitial assessment sample followed by a second sample

Examples include an independent laboratory or physician office without adequate clinical MI evaluation capability.

Denial Risk

Qualitative Outpatient Troponin Testing Does Not Meet Criteria

In the outpatient setting, qualitative measurement of cardiac troponin T or I does not meet criteria. This limitation reflects the lack of published scientific literature confirming that qualitative testing is required and beneficial for diagnosis and treatment.

Do not rely on qualitative outpatient troponin testing to satisfy coverage criteria.

Denial Risk

Non-Covered Acute Coronary Syndrome Biomarkers

For individuals presenting with signs and symptoms of acute coronary syndrome, measurement of the following biomarkers for the diagnosis or prognosis of myocardial infarction does not meet criteria.

Aspartate aminotransferase (AST/SGOT)
Cardiac creatine kinase isoenzyme MB (CK-MB)
Creatine kinase (CK)
Creatine kinase isoenzymes
Lactate dehydrogenase (LD/LDH)
Myoglobin
Copeptin
Troponin C

Denial Risk

C-Reactive Protein Not Covered for MI

Measurement of C-reactive protein for the diagnosis or prognosis of myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome does not meet criteria.

Do not bill C-reactive protein as a covered biomarker for MI diagnosis or prognosis under this policy.

Denial Risk

H-FABP Not Covered for MI

Measurement of heart-type fatty acid binding protein (H-FABP) for the diagnosis or prognosis of myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome does not meet criteria.

Do not bill H-FABP as a covered biomarker for MI diagnosis or prognosis under this policy.

Denial Risk

Other Cardiac Biomarkers Not Covered

Measurement of any other cardiac biomarker not listed in this policy for the diagnosis or prognosis of myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome does not meet criteria.

Unlisted cardiac biomarkers are not covered for MI diagnosis or prognosis under this policy.

Detailed presentation criteria are provided in Note 1

ACS abbreviation

AbbreviationACS

Full termAcute coronary syndrome

Terminology sectionTable of Terminology

AMI abbreviation

AbbreviationAMI

Full termAcute myocardial infarction

Terminology sectionTable of Terminology

BNP abbreviation

AbbreviationBNP

Full termBrain natriuretic peptide

Biomarker categoryNatriuretic peptide

CLIA '88 abbreviation

AbbreviationCLIA '88

Full termClinical Laboratory Improvement Amendments of 1988

SubjectClinical laboratory improvement requirements

CKMB abbreviation

AbbreviationCKMB

Full termCreatine kinase MB isoenzyme

BiomarkerCreatine kinase MB isoenzyme

ECG abbreviation

AbbreviationECG

Full termElectrocardiogram

Clinical assessmentElectrocardiographic assessment

HF abbreviation

AbbreviationHF

Full termHeart failure

Clinical conditionHeart failure

H-FABP abbreviation

AbbreviationH-FABP

Full termHeart-type fatty acid binding protein

BiomarkerHeart-type fatty acid binding protein

MI abbreviation

AbbreviationMI

Full termMyocardial infarction

Clinical conditionMyocardial infarction

NT-proBNP abbreviation

AbbreviationNT-proBNP

Full termN-terminal pro-B-type natriuretic peptide

Biomarker categoryNatriuretic peptide

hs-cTn abbreviation

Abbreviationhs-cTn

Full termHigh-sensitivity cardiac troponin

Test typeHigh-sensitivity cardiac troponin assay

Copeptin definition

Structure39-amino-acid C-terminal fragment

SourceCleaved from pro-arginine vasopressin (AVP)

After myocardial infarctionLevels increase rapidly and decline over the next two to five days

ST2 definition

FamilyMember of the interleukin-1 receptor family

IsoformsSoluble ST2 and membrane-bound ST2L

Clinical roleSoluble ST2 may bind IL-33 and is used as a marker of myocardial stress and fibrosis

BNP and NT-proBNP definition

Biomarker systemNatriuretic peptide system biomarker

ProductionProduced primarily by the left ventricle after proBNP cleavage

Clinical roleBNP and NT-proBNP can support evaluation of heart failure and its prognosis

Acute myocardial infarction definition

Myocardial injuryCardiac troponin concentration above the assay-specific 99th-percentile upper reference limit

Biomarker patternRising and/or falling cardiac troponin pattern

Additional requirementClinical evidence of ischemia

Myocardial infarction definition

Biomarker patternRise and/or fall in cardiac biomarker values, preferably cardiac troponin

ThresholdAt least one value above the 99th percentile of the upper reference limit

Additional criterionAt least one clinical, electrocardiographic, imaging, or angiographic criterion

Clinically relevant MI after coronary revascularization definition

ProceduresPercutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)

BiomarkersPost-procedure CK-MB or cardiac troponin increases

Additional findingsECG or clinical findings depending on the baseline biomarker pattern

Repeat cardiac troponin when initial value is nondiagnostic

TestCardiac troponin

When to repeatWhen the initial value is nondiagnostic

Intervals1 to 2 hours for high-sensitivity assays; 3 to 6 hours for conventional assays

Single-value high-sensitivity troponin timing requirement

TestHigh-sensitivity cardiac troponin

Timing requirementObtain the specimen at least 3 hours after symptom onset

PathwaySingle-value high-sensitivity cardiac troponin clinical decision pathway

Natriuretic peptide or high-sensitivity troponin testing in diabetes

PopulationIndividuals with diabetes

TestsNatriuretic peptide or high-sensitivity cardiac troponin

FrequencyAt least yearly

Serial high-sensitivity troponin sample requirement

TestHigh-sensitivity cardiac troponin

SamplesTwo samples when serial testing is used

Interval30 minutes to 3 hours between samples